In agreement with this, mutations in SUZ12, a component of EZH2-containing polycomb repressor complex 2 (PRC2), which inhibits CXXC4 expression,22 have been detected in the SCN-AML patient used for this study and others.6 Here, EZH2 is linked to acute myeloid leukemia.